Comparison Between Water Vapor Thermal Therapy and Prostatic Artery Embolization in Treatment of Benign Prostatic Hyperplasia

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexMale
Age50+
SponsorAin Shams University

About this trial

The aim of this study is to compare the effectiveness of Rezum therapy versus Prostatic Artery Embolization in managing moderate-to-severe lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH), with the primary endpoint being the improvement in the International Prostate Symptom Score (IPSS) over a 6-month follow-up period. Secondary endpoints include changes in post-void residual urine (PVR), maximum urinary flow rate (Qmax), patient-reported quality of life (QoL), and the preservation of ejaculatory and overall sexual function as assessed by validated questionnaires. This study aims to provide evidence-based guidance for optimizing treatment strategies for men with BPH, particularly those seeking alternatives to pharmacological therapy.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Age ≥50 years.

IPSS ≥13.

Prostate volume between 30-80 mL.

Maximum urinary flow rate (Qmax) ≤15 mL/sec in patients with voiding LUTs.

Disqualifiers

History or suspicion of prostate cancer.

Previous prostate surgery or minimally invasive BPH intervention.

Neurological bladder dysfunction.

Active urinary tract infection.

Trial design

Design model

Parallel

Treatments tested in this trial

  • Rezum

    Procedure/Surgery

    A single-use transurethral delivery device with an 18-gauge retractable needle is used to inject steam into the targeted area with a fixed depth of 10.25 mm via 12 emitter holes spaced at the needle tip with an angle of 120°. The procedure is visualized using an integrated cystoscope with a standard 4 mm 30° lens. Saline irrigation is used to improve visualization and to cool down the urethral surface during the procedure. Injection starts 1 cm distal to the bladder neck at 3 and 9 o'clock positions. Each injection deploys 0.5 ml of steam over 9 s at 103 °C raising the tissue temperature to 70 °C and it is recommended to wait for a couple of seconds postinjection to avoid loss of vapor through the puncture site. After each injection, the needle is retracted and reinserted 1 cm distal to the previous injection until the proximal edge of the verumontanum creating tissue ablation along the prostatic urethra.

  • Prostatic Artery Embolization

    Procedure/Surgery

    Sterilization of the groin will be done then puncture of the right femoral and/or left femoral artery will be done using puncture set after local anathesia. 6F vascular sheath, then a 5F cobra head catheter will be introduced in right and/or left femoral artery to catheterize one of the internal iliac artery then catheterizing its anterior division. An ipsilateral oblique view (30-40 degrees) and/or cranio-caudal view (10 degrees) will be obtained for differentiation of prostatic artery from other branches of anterior division \& for identification of prostatic artery origin. Selective catheterization of prostatic artery with suitable type of micro catheter and adjusted microwire angle. Embolizing material (400-500 micron microspheres) will be injected slowly and cautiously to avoid reflux under fluoroscopy guidance.

Treatment groups

30 Participants
are divided into 2 treatment groups
Group A: Arm A - Water Vapor Thermal Therapy (Rezum) groupExperimental treatment 1 intervention
Group B: Arm B - Prostatic Artery Embolization (PAE)Active comparator 1 intervention

Trial outcomes

Primary outcomes

1

Improvement in the International Prostate Symptom Score (IPSS) over a 6-month follow-up period.

Changes in a International Prostate Symptom Score (IPSS) will be measured to assess the degree of improvement after each procedure. Reduction of the score more than that it was before the procedure means better results and vice versa. (0-7) means mild symptoms , (8-19) means moderate symptoms and (20-35) means severe symptoms. The Unit of measure is a score .

Time frame
6 months follow up for each patient following the procedure

Secondary outcomes

1

1-Changes in post-voiding residual urine (PVR) assed by pelviabdomenal ultrasound in (mL) 2-Maximum urinary flow rate (Qmax) assessed by Uroflowmetry in (mL/s) 3-The preservation of ejaculatory function assessed by a validated questionnaire (MSHQ-EJD).

1. Post voiding residual urine will be assessed by PelviAbdomenal ultrasonography and the lower post voiding residual urine the more improvement and unit of measure is milliliter (mL). 2. maximum urinary flow rate will be assessed by uroflowmetry and the higher the maximum flow rate the more improvement and the unit of measure is milliliter(s)/second (mL/s). 3. Preservation of ejaculatory function will be assessed by asking the patient him self to compare his ejaculatory function pre and post procedure by a validated questionnaire (Male sexual health questionnaire) \[MSHQ-EjD\] and the unit of measure for this is a questionnaire.

Time frame
6 months follow up for each patient following the procedure

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.